|
WO2020263906A1
|
|
Sstr-targeted conjugates and formulations thereof
|
|
WO2020263907A1
|
|
Hsp90-binding conjugates and combination therapies thereof
|
|
WO2020205948A1
|
|
Hsp90-binding conjugates and formulations thereof
|
|
WO2020056205A1
|
|
Hsp90-targeting conjugates and formulations thereof
|
|
EP3801506A1
|
|
Combination therapy
|
|
CN112074288A
|
|
HSP 90-targeting conjugates and formulations thereof
|
|
KR20200141446A
|
|
Pharmaceutical compositions with reduced tert-butanol levels
|
|
WO2019118830A1
|
|
Hsp90-targeting conjugates and formulations thereof
|
|
AU2018354364A1
|
|
SSTR-targeted conjugates and formulations thereof
|
|
WO2018236796A1
|
|
Combination therapies comprising targeted therapeutics
|
|
US2020237746A1
|
|
Hsp90 targeted conjugates and particle formulations thereof
|
|
AU2018289351A1
|
|
Targeted therapeutics
|
|
WO2018222987A1
|
|
Targeted constructs
|
|
US2018296685A1
|
|
Targeted constructs and formulations thereof
|
|
EP3554558A1
|
|
Hsp90-targeting conjugates and formulations thereof
|
|
KR20190075938A
|
|
SSTR-targeted conjugates and their particles and formulations
|
|
WO2018022957A1
|
|
T cell binding conjugates and methods of use
|
|
WO2017210246A2
|
|
Penicillamine conjugates and particles and formulations thereof
|
|
TW201801751A
|
|
Targeted constructs and formulations thereof
|
|
US2020078468A1
|
|
Neurotensin receptor binding conjugates and formulations thereof
|
